BACKGROUND: Systematic data on discontinuation of statins in routine practice of medicine are limited. OBJECTIVE: To investigate the reasons for statin discontinuation and the role of statin-related events (clinical events or symptoms believed to have been caused by statins) in routine care settings. DESIGN: A retrospective cohort study. SETTING: Practices affiliated with Brigham and Women's Hospital and Massachusetts General Hospital in Boston. PATIENTS: Adults who received a statin prescription between 1 January 2000 and 31 December 2008. MEASUREMENTS: Information on reasons for statin discontinuations was obtained from a combination of structured electronic medical record entries and analysis of electronic provider notes by validated software. RESULTS: Statins were discontinued at least temporarily for 57 292 of 107 835 patients. Statin-related events were documented for 18 778 (17.4%) patients. Of these, 11 124 had statins discontinued at least temporarily; 6579 were rechallenged with a statin over the subsequent 12 months. Most patients who were rechallenged (92.2%) were still taking a statin 12 months after the statin-related event. Among the 2721 patients who were rechallenged with the same statin to which they had a statin-related event, 1295 were receiving the same statin 12 months later, and 996 of them were receiving the same or a higher dose. LIMITATIONS: Statin discontinuations and statin-related events were assessed in practices affiliated with 2 academic medical centers. Utilization of secondary data could have led to missing or misinterpreted data. Natural-language-processing tools used to compensate for the low (30%) proportion of reasons for statin discontinuation documented in structured electronic medical record fields are not perfectly accurate. CONCLUSION: Statin-related events are commonly reported and often lead to statin discontinuation. However, most patients who are rechallenged can tolerate statins long-term. This suggests that many of the statin-related events may have other causes, are tolerable, or may be specific to individual statins rather than the entire drug class. PRIMARY FUNDING SOURCE: National Library of Medicine, Diabetes Action Research and Education Foundation, and Chinese National Key Program of Clinical Science.
BACKGROUND: Systematic data on discontinuation of statins in routine practice of medicine are limited. OBJECTIVE: To investigate the reasons for statin discontinuation and the role of statin-related events (clinical events or symptoms believed to have been caused by statins) in routine care settings. DESIGN: A retrospective cohort study. SETTING: Practices affiliated with Brigham and Women's Hospital and Massachusetts General Hospital in Boston. PATIENTS: Adults who received a statin prescription between 1 January 2000 and 31 December 2008. MEASUREMENTS: Information on reasons for statin discontinuations was obtained from a combination of structured electronic medical record entries and analysis of electronic provider notes by validated software. RESULTS: Statins were discontinued at least temporarily for 57 292 of 107 835 patients. Statin-related events were documented for 18 778 (17.4%) patients. Of these, 11 124 had statins discontinued at least temporarily; 6579 were rechallenged with a statin over the subsequent 12 months. Most patients who were rechallenged (92.2%) were still taking a statin 12 months after the statin-related event. Among the 2721 patients who were rechallenged with the same statin to which they had a statin-related event, 1295 were receiving the same statin 12 months later, and 996 of them were receiving the same or a higher dose. LIMITATIONS: Statin discontinuations and statin-related events were assessed in practices affiliated with 2 academic medical centers. Utilization of secondary data could have led to missing or misinterpreted data. Natural-language-processing tools used to compensate for the low (30%) proportion of reasons for statin discontinuation documented in structured electronic medical record fields are not perfectly accurate. CONCLUSION: Statin-related events are commonly reported and often lead to statin discontinuation. However, most patients who are rechallenged can tolerate statins long-term. This suggests that many of the statin-related events may have other causes, are tolerable, or may be specific to individual statins rather than the entire drug class. PRIMARY FUNDING SOURCE: National Library of Medicine, Diabetes Action Research and Education Foundation, and Chinese National Key Program of Clinical Science.
Authors: Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant Journal: Stroke Date: 2002-09 Impact factor: 7.914
Authors: F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald Journal: N Engl J Med Date: 1996-10-03 Impact factor: 91.245
Authors: Jeffrey J Ellis; Steven R Erickson; James G Stevenson; Steven J Bernstein; Renee A Stiles; A Mark Fendrick Journal: J Gen Intern Med Date: 2004-06 Impact factor: 5.128
Authors: A S Brown; R G Bakker-Arkema; L Yellen; R W Henley; R Guthrie; C F Campbell; M Koren; W Woo; R McLain; D M Black Journal: J Am Coll Cardiol Date: 1998-09 Impact factor: 24.094
Authors: Seth S Martin; Laurence S Sperling; Michael J Blaha; Peter W F Wilson; Ty J Gluckman; Roger S Blumenthal; Neil J Stone Journal: J Am Coll Cardiol Date: 2015-04-07 Impact factor: 24.094
Authors: Rikki M Tanner; Monika M Safford; Keri L Monda; Benjamin Taylor; Ronan O'Beirne; Melanie Morris; Lisandro D Colantonio; Ricardo Dent; Paul Muntner; Robert S Rosenson Journal: Cardiovasc Drugs Ther Date: 2017-06 Impact factor: 3.727
Authors: Susan E Shoaf; John Ouyang; Olga Sergeyeva; Alvin Estilo; Hui Li; Deborah Leung Journal: Clin J Am Soc Nephrol Date: 2020-04-02 Impact factor: 8.237